Shandong Xinhua Pharmaceutical Company Limited
0719.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.83B
Close$
$10.78
96.2% upside
Current Fair Value
96.2% upsideUndervalued by 96.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.83 Billion |
|---|---|
| Enterprise Value | $4.34 Billion |
| Dividend Yield | $0.17 (1.01%) |
| Earnings per Share | $0.42 |
| Beta | -0.03 |
| Outstanding Shares | 696,683,435 |
Return
| Return on Equity | 4.07% |
|---|---|
| Return on Assets | 2.35% |
| Return on Invested Capital | 4.47% |
Valuation & Multiples
| P/E Ratio | 47.82 |
|---|---|
| PEG | -114.31 |
| Price to Sales | 0.46 |
| Price to Book Ratio | 0.69 |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | 15.22 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.47 |
| Debt to Equity | 0.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$0.20
Average shareholder expectationRevenue Estimate
$2.22 B
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$2.25 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shandong Xinhua Pharmaceutical Company Limited
7,240 employees
CEO: Wen Hui Xu Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers a...